{
  "id": 8948054,
  "title": "Novo offers low-dose CagriSema data as approval decision looms",
  "url": "https://urgent.news/2026/09/21/novo-offers-low-dose-cagrisema-data-as-approval-decision-looms",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-21T15:13:10.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/novo-offers-low-dose-cagrisema-data-as-approval-decision-looms/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Amid its capital markets day in London on Monday, Novo released data that suggested its investigational metabolic drug CagriSema was competitive with Eli Lilly’s Mounjaro when each was given at a low ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work",
        "url": "https://urgent.news/2026/09/21/stat-with-new-strategy-novo-outlines-plans-for-obesity-direct-to",
        "published": "2026-09-21T09:33:45.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}